Optimizing In Vivo Delivery & Dosing Strategies to Maximize mRNA Therapeutic Efficacy & Safety

• Comparing systemic vs local delivery strategies for achieving tissue-specific expression
• Examining how lipid type, ionizable components, and dosing schedule impact safety and immunogenicity
• Reviewing preclinical to clinical case studies where formulation or dosing adjustments significantly impacted trial outcomes

Speakers:

Ansgar Santel

Chief Executive Officer & Head of Translational Research & Alliance Management

Pantherna Therapeutics